Drug Combination Details
| General Information of the Combination (ID: C59959) | |||||
|---|---|---|---|---|---|
| Name | Ellagic acid NP Info | + | Sorafenib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| Up-regulation | Cytochrome c release | |||||
| In-vivo Model | Dietylnitrosamine and 2-acetylami nofluorene were used to induce HCC in male Sprague-Dawley rats. | |||||
| Experimental
Result(s) |
EA and SOR are effective on the HCC rat model through mitochondria and hepatocytes targeting. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic Effects of Ellagic Acid and Sorafenib on Hepatocytes and Mitochondria Isolated from a Hepatocellular Carcinoma Rat Model. Nutr Cancer. 2020 Oct 8;1-9. | |||
